Download PDF
TumorDiagnostik & Therapie 2019; 40(04): 233-236
DOI: 10.1055/a-0825-0533
Schwerpunkt Tumoren und Bewegungsapparat
© Georg Thieme Verlag KG Stuttgart · New York

Zielgerichtete Radionuklidtherapie zur Therapie ossärer Metastasen

Harun Ilhan
Further Information

Publication History

Publication Date:
06 May 2019 (online)

Also available at
    Permissions and Reprints

Im multimodalen Therapiekonzept ossärer Metastasen und der Schmerzpalliation stellen die verschiedenen Optionen der Radionuklidtherapie einen wichtigen Baustein dar. Wir geben einen Überblick zum Einsatz knochengängiger Radionuklide.
 

  • Literatur

  • 1 Macedo F. et al. Bone Metastases: An Overview. Oncol Rev 2017; 11: 321
    PubMedGoogle Scholar
  • 2 Lewington VJ. et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-958
    CrossrefPubMedGoogle Scholar
  • 3 Sartor O. et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007; 109: 637-643
    CrossrefPubMedGoogle Scholar
  • 4 Parker C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223
    CrossrefPubMedGoogle Scholar
  • 5 Gill MR. et al. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol 2017; 18: e414-e423
    CrossrefPubMedGoogle Scholar
  • 6 Ogawa K, Ishizaki A. Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases. Biomed Res Int 2015; 2015: 676053
    PubMedGoogle Scholar
  • 7 Ahmadzadehfar H. et al. Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning. PET Clin 2018; 13: 491-503
    CrossrefPubMedGoogle Scholar
  • 8 Silberstein EB, Elgazzar AH, Kapilivsky A. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med 1992; 22: 17-27
    PubMedGoogle Scholar
  • 9 Robinson RG. et al. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274: 420-424
    CrossrefPubMedGoogle Scholar
  • 10 Palmedo H. et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003; 21: 2869-2875
    CrossrefPubMedGoogle Scholar
  • 11 Biersack HJ. et al. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 2011; 52: 1721-1726
    CrossrefPubMedGoogle Scholar
  • 12 Sinzinger H, Weiss K, Hiltunen J. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP. Anticancer Res 2009; 29: 3393-3395
    PubMedGoogle Scholar
  • 13 Yuan J. et al. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med 2013; 38: 88-92
    CrossrefPubMedGoogle Scholar
  • 14 Agarwal KK. et al. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging 2015; 42: 79-88
    CrossrefPubMedGoogle Scholar
  • 15 Saad F. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016; 17: 1306-1316
    CrossrefPubMedGoogle Scholar